Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $31.00 Average Target Price from Brokerages

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have received an average recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $30.50.

Several research firms recently weighed in on TYRA. HC Wainwright reduced their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Wedbush reissued an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Finally, UBS Group began coverage on Tyra Biosciences in a research note on Tuesday. They set a “buy” rating and a $28.00 price target for the company.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, CFO Alan Fuhrman bought 9,500 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares in the company, valued at $205,584. This represents a 283.67 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nina S. Kjellson sold 27,493 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the sale, the director now directly owns 458,506 shares in the company, valued at approximately $7,592,859.36. The trade was a 5.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 84,160 shares of company stock valued at $1,827,047 over the last three months. Company insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Tyra Biosciences by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of Tyra Biosciences during the third quarter valued at about $278,000. Barclays PLC increased its holdings in shares of Tyra Biosciences by 200.5% in the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock worth $884,000 after buying an additional 25,106 shares during the period. State Street Corp lifted its stake in shares of Tyra Biosciences by 4.4% in the 3rd quarter. State Street Corp now owns 384,732 shares of the company’s stock valued at $9,045,000 after acquiring an additional 16,248 shares during the last quarter. Finally, Polar Asset Management Partners Inc. purchased a new stake in Tyra Biosciences during the 3rd quarter valued at about $2,071,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Up 0.1 %

Tyra Biosciences stock opened at $15.97 on Tuesday. The firm has a market capitalization of $808.13 million, a price-to-earnings ratio of -9.92 and a beta of 1.04. The firm’s fifty day moving average price is $15.48 and its two-hundred day moving average price is $19.22. Tyra Biosciences has a 1-year low of $11.32 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, research analysts forecast that Tyra Biosciences will post -1.57 EPS for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.